CD93 serves as a potential biomarker of gastric cancer and correlates with the tumor microenvironment

Table 1 Univariate and multivariate Cox regression analysis of overall survival

Characteristics	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Age	1.02	1.01-1.04	0.002	1.03	1.02-1.05	< 0.001
Grade
G1	Reference
G2	2.64	0.36-19.18	0.337
G3	3.53	0.49-25.38	0.209
G4	3.54	0.37-34.07	0.274
Gender	1.31	0.91-1.9	0.145
Stage
I	Reference			Reference
II	1.45	0.75-2.8	0.268	1.41	0.73-2.74	0.307
III	2.11	1.14-3.91	0.018	1.99	1.07-3.71	0.03
IV	3.65	1.81-7.39	< 0.001	4.97	2.41-10.22	< 0.001
CD93 (high vs low)	1.6	1.09-2.35	0.017	1.62	1.09-2.4	0.017

HR: Hazard ratio.

Table 2 Baseline patient characteristics

Characteristics	high-CD93 (n = 220)	low-CD93 (n = 114)	Overall (n = 334)
Age, yr (mean ± SD)	64.8 ± 12.8	64.1 ± 10.3	64.5 ± 12.0
Gender, n (%)
Female	72 (32.7)	48 (42.1)	120 (35.9)
Male	148 (67.3)	66 (57.9)	214 (64.1)
Grade, n (%)
G1	4 (1.8)	4 (3.5)	8 (2.4)
G2	66 (30.0)	50 (43.9)	116 (34.7)
G3	143 (65.0)	59 (51.8)	202 (60.5)
GX	7 (3.2)	1 (0.9)	8 (2.4)
pT, n (%)
T1	5 (2.3)	10 (8.8)	15 (4.5)
T2	45 (20.5)	25 (21.9)	70 (21.0)
T3	103 (46.8)	53 (46.5)	156 (46.7)
T4	67 (30.5)	26 (22.8)	93 (27.8)
pN, n (%)
N0	63 (28.6)	40 (35.1)	103 (30.8)
N1	62 (28.2)	24 (21.1)	86 (25.7)
N2	43 (19.5)	26 (22.8)	69 (20.7)
N3	48 (21.8)	22 (19.3)	70 (21.0)
NX	4 (1.8)	2 (1.8)	6 (1.8)
pM, n (%)
M0	194 (88.2)	105 (92.1)	299 (89.5)
M1	17 (7.7)	4 (3.5)	21 (6.3)
MX	9 (4.1)	5 (4.4)	14 (4.2)
Stage, n (%)
Stage I	24 (10.9)	22 (19.3)	46 (13.8)
Stage II	75 (34.1)	35 (30.7)	110 (32.9)
Stage III	96 (43.6)	48 (42.1)	144 (43.1)
Stage IV	25 (11.4)	9 (7.9)	34 (10.2)